Out-of-pocket cost of naloxone may keep many uninsured from using life-saving treatment

By RAND Corporation
| August 25, 2022

The cost of buying the opioid antidote naloxone is out of reach for many uninsured Americans, a hurdle that may keep the treatment from saving more people who overdose on opioids.

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...